NCT00046072已完成2 期
A Double-Blind, Placebo-Controlled Study of E5564, A Lipid A Antagonist, Administered by Twice Daily Infusions in Patients With Severe Sepsis
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Eisai Inc.
- 入组人数
- 300
- 试验地点
- 17
研究概览
简要总结
Sepsis is a serious condition where there is inflammation and damage to body tissue, usually caused by an infection. This infection can lead to decreased function of vital body organs and in some cases may lead to permanent health problems or death.
Much of the injury is due to endotoxin, a harmful substance produced by certain types of bacteria. An endotoxin antagonist is designed to block the effects of endotoxin.
This study is designed to study the safety and efficacy when treating patients with severe sepsis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Presently admitted, or about to be transferred, to the ICU.
- •Women of Child-bearing potential must have a negative serum (or urine) hCG assay within 24 hours prior to drug administration.
- •Any Race.
- •Severe Sepsis [newly developed respiratory failure, refractory shock, renal dysfunction, hepatic dysfunction, or metabolic acidosis and at least three signs of SIRS (systematic inflammatory response syndrome)].
- •Objective signs of infection likely to be caused by a bacterial or fungal pathogen.
- •Patients must receive study medication within 8 to 12 hours of recognition of the initial sepsis-related organ failure.
- •APACHE Predicted risk of mortality score between 20% and 80%.
- •An intent by physicians and family to aggressively treat the patient for the 28 day study period.
排除标准
- •Cardiogenic or hypovolemic shock.
- •Acute third degree burns involving >20% of body surface.
- •Recipients of non-autologous organ transplants within the past year.
- •Pregnancy.
- •Chronic vegetative state.
- •Uncontrolled serious hemorrhage (.2 units of blood/platelets in the previous 24 hours). Patients may be considered for enrollment if bleeding has stopped and patients are still otherwise qualified.
- •Unwilling or unable to be fully evaluated for all follow-up visits.
- •Patients who are classified as "Do not resusitate" or "Do not treat."
- •Patients who develop severe sepsis <36 hours post trauma or post-surgery. Patients may be considered for enrollment >36 hours post-trauma or post-surgery, if they meet other inclusion criteria.
- •Patients with a predicted risk of mortality score of <20% or >80% after recognition of qualifying organ failure.
- •Patients with a predicted risk of mortality of <51% for whom Xigris® use is planned.
研究者
研究点 (17)
Loading locations...
相似试验
已完成
3 期
Hydrocortisone for Prevention of Septic ShockSevere SepsisNCT00670254Charite University, Berlin, Germany380
暂停
不适用
A Randomised Trial on the Saftely and Efficacy of GR270774 in the Treatment of Gram-negative Sepsis in AdultGram-Negative Bacterial InfectionsSepsisNCT00563134Hospital Authority, Hong Kong1,800
已完成
不适用
Study the Impact of Statins in Septic ShockSeptic ShockNCT02681653Sanjay Gandhi Postgraduate Institute of Medical Sciences40
Unknown
不适用
A Prospective Observational Study of SepsisSepsisNCT05309889Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University174
招募中
不适用
Sepsis - Long-term sequelae, risk factors, health care utilization and costsR65.0R65.1R57.2Systemic Inflammatory Response Syndrome of infectious origin without organ failureSystemic Inflammatory Response Syndrome of infectious origin with organ failureSeptic shockDRKS00016340Center for Sepsis Control & CareUniversitätsklinikum Jena200